Bayer’s experimental Parkinson’s disease therapy made from stem cells will soon enter late-stage studies, marking a key test for regenerative medicine in neurologic conditions. The therapy, known as bemdaneprocel, is being developed by BlueRock Therapeutics, a Bayer...
Clinical Trial Assesses Safety and Tolerability of Escalating Doses of ANPD001 Autologous, Dopaminergic Neuronal Cell Replacement Therapy SAN DIEGO, Jan. 13, 2025 /PRNewswire/ — Aspen Neuroscience, Inc. has successfully completed dose escalation and the first...
Next-generation gene therapy demonstrates best-in-class potential with majority of neurons transduced in substantia nigra and high levels of GCase supplementation after single IV infusion Broad GCase elevation achieved in NHPs, while significantly detargeting the...
PET imaging scans demonstrated evidence of the engrafted cells surviving in both the low- and high-dose cohorts. (iStock / Getty Images Plus) Things are continuing to look up for Bayer’s Parkinson’s disease cell therapy, with the German pharma giant finally offering a...